Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07231952 · ClinicalTrials.gov registry record · Phase 2

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

A Phase 2 study of Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
8
Study locations

NCT07231952 is a Phase 2 study of Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 40 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07231952, a Phase 2 study of Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)

Conditions Studied

Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma

Interventions

  • DRUG Venetoclax
  • DRUG Rituximab
  • DRUG Pirtobrutinib

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk - Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memoral Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Massachusetts

  • Beth Israel Deaconess Medical Center (Data Collection Only) - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-11-11
Est. Completion 2028-04-11
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07231952

The ClinicalTrials.gov registry entry for NCT07231952 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT07231952 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07231952 about?

NCT07231952 is a clinical study titled "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)". The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)

What is the current status of trial NCT07231952?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-11-11. Estimated completion is 2028-04-11.

What conditions does trial NCT07231952 study?

This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma.

What interventions are being tested in trial NCT07231952?

The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG), Pirtobrutinib (DRUG).

Who is sponsoring clinical trial NCT07231952?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07231952 being conducted?

This trial has 8 study locations across Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Waldenstrom Macroglobulinemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Waldenstrom Macroglobulinemia

All registered trials for this condition

Lymphoplasmacytic Lymphoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.